Xeris Pharmaceuticals Stock Alpha and Beta Analysis
| XERS Stock | USD 3.58 0.03 0.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Xeris Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Xeris Pharmaceuticals over a specified time horizon. Remember, high Xeris Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Xeris Pharmaceuticals' market risk premium analysis include:
Beta 0.47 | Alpha 0.42 | Risk 2.63 | Sharpe Ratio 0.15 | Expected Return 0.39 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Xeris |
Xeris Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Xeris Pharmaceuticals market risk premium is the additional return an investor will receive from holding Xeris Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Xeris Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Xeris Pharmaceuticals' performance over market.| α | 0.42 | β | 0.47 |
Xeris Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Xeris Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Xeris Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Xeris Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Xeris Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Xeris Pharmaceuticals shares will generate the highest return on investment. By understating and applying Xeris Pharmaceuticals stock market price indicators, traders can identify Xeris Pharmaceuticals position entry and exit signals to maximize returns.
Xeris Pharmaceuticals Return and Market Media
The median price of Xeris Pharmaceuticals for the period between Thu, Sep 12, 2024 and Wed, Dec 11, 2024 is 3.04 with a coefficient of variation of 7.97. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 3.09, and mean deviation of 0.2. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Zevra Therapeutics Moves 9.1 percent Higher Will This Strength Last | 09/25/2024 |
2 | Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635 | 10/04/2024 |
3 | Oppenheimer holds Outperform on Xeris Pharmaceuticals, sees shares as undervalued - Investing.com | 10/23/2024 |
4 | Xeris Biopharma Q3 Earnings Taking a Look at Key Metrics Versus Estimates | 11/08/2024 |
5 | Disposition of 2640 shares by Steven Pieper of Xeris Pharmaceuticals at 1.55 subject to Rule 16b-3 | 11/22/2024 |
6 | Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference | 11/26/2024 |
7 | Disposition of 15692 shares by John Shannon of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | 12/06/2024 |
About Xeris Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Xeris or other stocks. Alpha measures the amount that position in Xeris Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2023 | 2024 (projected) | Payables Turnover | 2.54 | 2.48 | 1.59 | Days Of Inventory On Hand | 398.88 | 494.88 | 282.15 |
Xeris Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Xeris Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Xeris Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Xeris Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Xeris Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Xeris Pharmaceuticals' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Xeris Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.